Despite winning an FDA green light nearly three months ago for its first wearable insulin delivery system, Embecta is now ...

Embecta announced today that it discontinued its insulin patch pump program and plans to initiate a restructuring plan.

Kurdikar, CEO of Embecta (EMBC) said, “As our stand-up work nears completion and following an in-depth review of our ...

BTIG upgraded Embecta (EMBC) to Buy from Neutral with a $26 price target Shares gained about 30% in Tuesday trading as investors rewarded ...

BofA raised the firm’s price target on Embecta (EMBC) to $20 from $17 and keeps an Underperform rating on the shares after the company ...

After adding nearly 30% in the previous session following its better-than-expected Q4 results for FY24, Embecta (NASDAQ:EMBC) ...

On Tuesday, Embecta Corp (NASDAQ:EMBC) posted the fourth-quarter adjusted EPS of 45 cents, beating the consensus of 36 cents ...

B, consensus $1.12B. Unlock your investing potential with TipRanks Premium - Now At 40% OFF! Make smarter investments with ...

Embecta also said it expects to earn between $2.70 and $2.90 a share on an adjusted basis for all of 2025, easily surpassing the average analyst estimate of $2.27 per share. Revenue is anticipated at ...

Embecta (NASDAQ:EMBC – Get Free Report) is scheduled to release its earnings data before the market opens on Tuesday, ...

Algert Global LLC trimmed its holdings in shares of Embecta Corp. (NASDAQ:EMBC – Free Report) by 31.8% in the third quarter, ...

CEO Dev Kurdikar said the decision may “come as a surprise” as Embecta just received FDA clearance for a patch pump, but the company “did not intend to do a full market launch of this product.” ...